Ssilverchair, page-6

Not at all, people with Vitiligo have very little to help them. The initial results seen from Scenesse are phenomenal, I see no reason not to expect fantastic P3 results and quick approval for vitiligo. The phase three trial will be completed quite fast, they're actively recruiting now so I'd be expecting updates soon. First patient in the trial was treated in October of last year... commercialisation is close imo

More data from the XP trials should come soon as well, not that XP is a very large market (still an additional market for CUV to be a monopoly player in), but most importantly the data will help prove the importance of this drug in sun protection etc